Author/Authors :
Nazemalhosseini Mojarad، Ehsan نويسنده Gastroenterology and Liver Disease Research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. , , Kishani Farahani، Roya , نويسنده Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, Shahid Beheshti University of Medical , , Montazer Haghighi، Mahdi نويسنده Department of Biology, Science Faculty, East Tehran Branch, Islamic Azad University, Tehran, Iran , , Asadzadeh Aghdaei، Hamid نويسنده Basic and Molecular epidemiology of Gastrointestinal Disorders Research Center, Shahid Beheshti University Medical Sciences, Tehran , , J.K. Kuppen، Peter نويسنده Department of Surgery, Leiden University Medical Center, Leiden, , , Zali، Mohammad Reza نويسنده Department of Celiac Disease, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran ,
Abstract :
Knowledge about the clinical significance of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutations in
colorectal cancer (CRC) is growing. BRAF encodes a protein kinase involved with intracellular signaling and cell
division. The gene product is a downstream effector of Kirsten Ras 1(KRAS) within the RAS/RAF/MAPK cellular
signaling pathway. Evidence suggests that BRAF mutations, like KRAS mutations, result in uncontrolled, non–growth
factor-dependent cellular proliferation. Similar to the rationale that KRAS mutation precludes effective treatment with
anti-EGFR drugs. Recently, BRAF mutation testing has been introduced into routine clinical laboratories because its
significance has become clearer in terms of effect on pathogenesis of CRC, utility in differentiating sporadic CRC from
Lynch syndrome (LS), prognosis, and potential for predicting patient outcome in response to targeted drug therapy. In
this review we describe the impact of BRAF mutations for these aspects.
Keywords: Colorectal Cancer, BRAF mutation, Prognosis value.
(Please cite as: Nazemalhosseini Mojarad E, Kishani Farahani R, Montazer Haghighi M, Asadzadeh Aghdaei H,
Kuppen PJ, Zali MR. Clinical implications of BRAF mutation test in colorectal cancer. Gastroenterol Hepatol Bed
Bench 2013;6(1):6-13).
